早期乳腺癌骨髓播散肿瘤细胞:国际汇总分析
PADDY 国际汇总分析纳入 11 个中心 10,307 例初诊未治疗早期乳腺癌患者,骨髓 DTC 阳性率 27.3%。多因素分析显示 DTC 阳性是总生存、无病生存和远处无病生存的独立不良预后标志物,且与局部区域复发无关。
要点
- 早期乳腺癌骨髓 DTC 阳性率 27.3%,与更高肿瘤分级、更大肿瘤、淋巴结阳性及 HER2 阳性相关。
- DTC 阳性是总生存(HR 1.23)、无病生存(HR 1.30)和远处无病生存(HR 1.30)的独立不良预后因素。
- DTC 与局部区域无复发生存无关(HR 1.21,95%CI 0.68-2.16,p=0.512)。
核心结论
- 骨髓 DTC 是早期乳腺癌独立预后标志物,其转移启动潜能异质性与肿瘤休眠概念一致。
研究设计与样本
- PADDY 为国际汇总分析,收集 11 个中心初诊未接受抗癌治疗且骨髓采样的早期乳腺癌患者个体数据,用抗体染色上皮细胞角蛋白识别 DTC,多因素 Cox 回归比较 DTC 阳性与阴性患者生存。
- 共纳入 10,307 例患者,其中 2,814 例(27.3%)为 DTC 阳性。
主要发现
- DTC 检测与更高肿瘤分级、更大肿瘤尺寸、淋巴结阳性、雌激素受体和孕激素受体阴性及 HER2 阳性相关(均 p<0.001)。
- 多因素分析显示 DTC 检测是总生存的独立预后标志物(HR 1.23,95%CI 1.06-1.43,p=0.006)。
- DTC 检测是无病生存的独立预后标志物(HR 1.30,95%CI 1.12-1.52,p<0.001)。
- DTC 检测是远处无病生存的独立预后标志物(HR 1.30,95%CI 1.08-1.56,p=0.006)。
- 局部区域无复发生存与 DTC 检测无关联(HR 1.21,95%CI 0.68-2.16,p=0.512)。
临床怎么用
- 骨髓 DTC 检测可用于早期乳腺癌初诊患者的预后分层,DTC 阳性提示总生存、无病生存和远处无病生存较差。
- DTC 阳性与局部区域复发无关,临床决策中不应据此强化局部治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Presence of disseminated tumour cells (DTCs) in the bone marrow (BM) has been described as a surrogate of residual disease in patients with early breast cancer (EBC). PADDY (Pooled Analysis of DTC Detection in Early Breast Cancer) is a large international analysis of pooled data that aimed to assess the prognostic impact of DTCs in patients with EBC. EXPERIMENTAL DESIGN: Individual patient data were collected from 11 centres. Patients with EBC and available follow-up data in whom BM sampling was performed at the time of primary diagnosis before receiving any anticancer treatment were eligible. DTCs were identified by antibody staining against epithelial cytokeratins. Multivariate Cox regression was used to compare the survival of DTC-positive versus DTC-negative patients. RESULTS: In total, 10,307 patients were included. Of these, 2814 (27.3%) were DTC-positive. DTC detection was associated with higher tumour grade, larger tumour size, nodal positivity, oestrogen receptor and progesterone receptor negativity, and HER2 positivity (all p < 0.001). Multivariate analyses showed that DTC detection was an independent prognostic marker for overall survival, disease-free survival and distant disease-free survival with hazard ratios (HR) and 95% confidence intervals (CI) of 1.23 (95% CI: 1.06-1.43, p = 0.006), 1.30 (95% CI: 1.12-1.52, p < 0.001) and 1.30 (95% CI: 1.08-1.56, p = 0.006), respectively. There was no association between locoregional relapse-free survival and DTC detection (HR 1.21; 95% CI 0.68-2.16; p = 0.512). CONCLUSIONS: DTCs in the BM represent an independent prognostic marker in patients with EBC. The heterogeneous metastasis-initiating potential of DTCs is consistent with the concept of cancer dormancy.
引用
- Hartkopf AD, Brucker SY, Taran FA, et al. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. Eur J Cancer. 2021. PMID: 34265505. doi:10.1016/j.ejca.2021.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。